News Release

RIBOMIC presented results of Phase 1/2a Clinical Trial of RBM-007 (SUSHI) in Subjects with Wet Age-Related Macular Degeneration at Two Conferences

February 25, 2020

- RIBOMIC presented results of Phase 1/2a Clinical Trial of RBM-007 (SUSHI) in Subjects with Wet Age-Related Macular Degeneration at Angiogenesis, Exudation, and Degeneration 2020 and at 43rd Annual Macula Society Meeting
- RBM-007 was well-tolerated, no systemic or ocular serious adverse events.
- RBM-007 showed efficacy trends in favor of RBM-007 in OCT analysis.
- A novel pathway to treat exudative AMD

TOKYO, February 25, 2020 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (Code Number: 4591), today announced that safety and efficacy data in the phase 1/2 trial of RBM-007 for the treatment of exudative age-related macular degeneration (AMD) were presented at two conferences; Angiogenesis, Exudation, and Degeneration 2020 and 43rd Annual Macula Society Meeting.

On Feb 9th at Angiogenesis, Exudation, and Degeneration 2020 in Miami, FL., results were presented by Quan Dong Nguyen, M.D., Professor of Ophthalmology at Byers Eye Institute, Stanford University School of Medicine as an oral presentation. Dr. Nguyen presented that SUSHI study demonstrated the safety and tolerability of RBM-007, with no systemic or ocular serious adverse events, and also efficacy trends in favor of RBM-007.

On Feb 21th at 43rd Annual Macula Society Meeting in San Diego, CA, results were presented by Rajendra S. Apte, MD, PhD, Paul A. Cibis Distinguished Professor of Ophthalmology, Washington University School of Medicine as an oral presentation. As an experts in FGF2 in ophthalmology area, Dr. Apte introduced the FGF2 inhibition using RBM-007 as a novel pathway to treat exudative AMD.

SUSHI Study was completed in June 2019. Phase 2 POC Study (TOFU Study) is now on going.

About RBM-007 and development background

RBM-007 is a novel oligonucleotide-based aptamer with potent anti-FGF2 (fibroblast growth factor 2) activity. Currently approved therapies for wet AMD, intravitreal injections of anti-VEGF drugs, have shown dramatic visual benefits for wet AMD patients. However, a significant portion of wet AMD patients exhibit incomplete response to therapy, and over the extended management course can lose vision, with the formation of submacular fibrosis as one risk factor. RIBOMIC investigated a novel therapy for wet AMD targeting fibroblast growth factor 2 (FGF2), which is implicated in not only angiogenesis but also fibrosis in several diseases, and created RBM-007, a novel oligonucleotide-based aptamer with potent anti-FGF2 activity. RBM-007 is chemically

synthesized, and pharmacokinetic studies of RBM-007 in the rabbit vitreous revealed high and relatively long-lasting profiles, which are superior to the other approved anti-VEGF drugs. The dual action of RBM-007 (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for wet AMD.

About SUSHI study
The Phase 1/2a Safety and ocUlar tolerability of a Single intravitreal (IVT) injection of RBM-007 in subjects witH exudatIve age-related macular degeneration (SUSHI) study is an open-label, dose escalation study with 9 subjects who had previously received ≥3 anti-VEGF treatments without resolution of wet AMD. Study eyes received a single intravitreal injection of RBM-007 in 3 sequential dose cohorts (3 subjects/cohort): 0.2 mg (Cohort 1), 1.0 mg (Cohort 2) and 2.0 mg (Cohort 3). The primary study endpoint was at Day 28, with follow-up through Day 56. Study visits included ETDRS best-corrected visual acuity (BCVA), complete ophthalmologic exam, fluorescein angiography, spectral domain-OCT, OCT-angiography and PK/PD RBM-007 plasma levels. This is the first clinical study of RBM-007. Currently no other FGF2 inhibitors are reported to be in the clinical stage.

See ClinicalTrials.gov for more information.
https://clinicaltrials.gov/ct2/show/NCT03633084

About TOFU study
A MulTi-Center, RandOmized, Double Masked and Active Controlled Phase II Study Assessing the EFficacy and Safety of Intravitreal Injections of **RBM-007** monotherapy and RBM-007 in Combination with Eylea® Compared to Eylea® Monotherapy in SUbjects with Wet Age-related Macular Degeneration (TOFU Study) is Phase 2 Study assessing the safety, efficacy and durability of RBM-007.

See ClinicalTrials.gov for more information.
https://clinicaltrials.gov/ct2/show/NCT04200248

About wet Age-related Macular Degeneration
Wet (exudative) age-related macular degeneration, is the leading cause of blindness in the United States and Europe. It is caused by the formation of abnormal and leaky new blood vessels under the retina, termed choroidal neovascularization. The leakage of fluid from the vessels causes retinal thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision.

ABOUT RIBOMIC
RIBOMIC is a bio-venture company centered on drug discovery. The company is engaged in the field of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company's core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, pain and many other problems.
See RIBOMIC website for more information.
https://www.ribomic.com/eng/

Forward-Looking Statements
This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief

and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.
Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

Contacts for inquiries or additional information:
RIBOMIC Inc.
Corporate Planning Department
ir.inquiry@ribomic.com